60th Annual Meeting of the Japanese Society of Neurology

Session information

Print

Symposium

[S-27] Current topics in Guillain-Barré syndrome - from pathophysiology to clinical features

Fri. May 24, 2019 1:45 PM - 3:45 PM Room 6 (Osaka International Convention Center 10F Conference Room 1009)

Chair:Kenichi Kaida(Division of Neurology, Department of Internal Medicine, National Defense Medical College, Japan), Atsuro Chiba(Departemnt of Neurology, School of Medicine, Kyorin University, Japan)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

[S-27-1] Recent advances of anti-glycolipid antibody research in GBS

Hugh Willison (University of Glasgow, Scotland)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

[S-27-2] Ca2+-dependent anti-GQ1b antibody: From a new assay method to an insight for paranodal gangliosides

Atsuro Chiba (Department of Neurology, Faculty of Medicine, Kyorin University, Japan)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

[S-27-3] New observations from the International GBS Outcome Study (IGOS)

Bart Jacobs (Departments of Neurology and Immunology, Erasmus University Medical Center, The Netherlands)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

[S-27-4] Nodopathy: The third electrophysiologic category in Guillain-Barré syndrome

Satoshi Kuwabara (Department of Neurology, Graduate School of Medicine, Chiba University, Japan)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

[S-27-5] Guillain-Barré syndrome in Japan; clinical features and prediction of prognosis

Yuko Yamagishi1, Motoi Kuwahara1, Hidekazu Suzuki1,2, Makoto Samukawa1, Japanese GBS study group Japanese GBS study group3, Susumu Kusunoki1 (1.Department of Neurology, Kindai University, Faculty of Medicine, Japan, 2.Department of Neurology, Ikuwakai Memorial Hospital, 3.Japanese GBS study group)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.